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ABSTRACT 
 
CHARACTERIZATION OF AN EVOLVING SEROTONIN TRANSPORTER 
COMPUTATIONAL MODEL 
 
 
 
By 
Laura M. Geffert 
May 2013 
 
Thesis supervised by Dr. Christopher K. Surratt 
A major obstacle for developing new antidepressants has been limited knowledge 
of the structure and function of a central target, the serotonin transporter (SERT).  
Established SERT inhibitors (SSRIs) were docked to an in silico SERT model to identify 
likely binding pocket amino acid residues.  When mutated singly, no one of five 
implicated residues was critical for high affinity in vitro binding of SSRIs or cocaine.  
The in silico SERT model was used in ligand virtual screening (VS) of a small molecule 
structural library.  Selected VS “hit” compounds were procured and tested in vitro; 
encouragingly, two compounds with novel structural scaffolds bound SERT with modest 
affinity.  The combination of computational modeling, site-directed mutagenesis and 
pharmacologic characterization can accelerate binding site elucidation and the search for 
novel lead compounds.  Such compounds may be tailored for improved serotonin 
 v 
 
receptor selectivity and reduced affinity for extraneous targets, providing superior 
antidepressants with fewer adverse effects.  
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Introduction 
 
A. Serotonin and its modulation in the synapse 
Serotonin is a signaling molecule in the brain and in the periphery that functions to 
regulate mood, weight, sleep, digestive and motor functions. The modulation of serotonin 
underlies the behavioral effects of various psychoactive drugs.  Modulation of the 
neurotransmitter (NT) has been identified as an important target for a wide range of drugs 
for the treatment of mood, anxiety, and behavioral disorders. It is inactivated by synaptic 
clearance, mediated by the serotonin transporter (SERT) protein (Figure 1), a member of 
the monoamine transporter (MAT) family of proteins.  The SERT translocates serotonin 
across the cell plasma membrane via electrogenic transport, driven by the neuronal 
inward Na
+
 gradient.  Co-transport of Cl
- 
is required of all MATs, and the SERT 
additionally antiports (exports) K
+
.  Selective serotonin reuptake inhibitors (SSRIs) and 
tricyclic antidepressants (TCAs) both inhibit the reuptake of serotonin into the 
presynaptic neuron, while SSRIs bind selectively to SERT.  This results in synaptic 
pooling of the NT, leading to an increase in downstream signal transduction and 
propagation of the NT’s effects.  The binding site for serotonin is formed by some of the 
12 SERT transmembrane domains.  An extracellular gate formed by connections between 
two amino acids blocks access to the primary substrate (serotonin) binding site when the 
transporter is in the closed conformation.  This conformation will change when both a 
substrate and sodium ions are bound, which ensures that transport movement of the 
substrate across the membrane will be coupled with sodium.   
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Figure 1: 3D Representation of the SERT Protein using Dr. Manepalli’s SERT model. 
Figure was created using MOE 2008. 
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B. SERT structure 
The sequence of hSERT is comprised of 630 amino acid residues with 12 transmembrane 
spanning regions (TM domains).  Residues conserved among the NSS proteins are 
typically more important for transporter infrastructure or the translocation mechanism; 
ones unique to the MATs are more likely to play a role in specificity of substrate binding.  
Those unique to the SERT may contribute to SSRI binding sites, for example.  MAT 
inhibitor binding site(s) have not yet been reliably defined, and SERT-inhibitor cocrystals 
do not appear to be pending.  Obtaining a MAT X-ray crystal will be difficult, as is the 
case for most integral membrane proteins.  A major challenge of membrane protein 
crystallography is obtaining and purifying sufficient amounts of the protein.  It is 
challenging to select the proper detergent to ensure the structure of the protein is the same 
as in the lipid bilayer (Matthew et al., 2006).  In the absence of a high-resolution 
structure, virtual molecular models and biochemical/pharmacological experiments must 
provide the structure/function information.   
 
C. Leucine transporter (LeuT) crystallization 
The LeuT bacterial leucine transporter belongs to a family of neurotransmitter/sodium 
symporters (NSS), also known as the solute carrier 6 (SLC6) gene family.  Electrogenic 
transport of a neurotransmitter substrate across the cell membrane by NSSs is driven by 
the Na+/K+-ATPase-generated Na+ gradient.  Included in this family of symporters are 
the MATs, distantly-related homologs of LeuT.  Prior to the LeuT crystallization, the 3-D 
structure of NSS proteins was only vaguely understood.  Multiple approaches were used 
to provide clues as to which NSS residues contributed to the general protein 
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infrastructure, which residues played a role in substrate or ion recognition, and which 
residues were most likely responsible for a pharmacological pattern unique to a given 
transporter.  MAT primary sequence alignments guided delineation of each TM domain 
(Goldberg et al., 2003; Surratt et al., 2005).  The sequence alignment with SERT 
(partially shown in Figure 2) also provided clues to NSS structure, which led to many 
site-directed mutants (Henry et al., 2003). Pharmacological examination of those changes 
(wildtype protein vs. mutant) can provide notable insights.  The substituted cysteine 
accessibility mutagenesis (SCAM) methodology provides an approach to identify the 
residues in the membrane-spanning segments that line the transporter and has also 
contributed to elucidating likely MAT ligand binding cavities and general transmembrane 
domain infrastructure (Loland et al., 2004; Henry et al., 2006).  Unfortunately, these 
approaches only circumstantially implicate a given residue or protein region as a 
component of the binding pocket. 
 
The structure of LeuT was crystallized in 2005 (Yamashita et al., 2005).  Since LeuT was 
crystallized, the LeuT crystal has proved to be an excellent template for the construction 
of experimentally validated models (Beuming et al., 2006; Indarte, et al., 2008).  These 
models have guided numerous site-directed mutagenesis studies for the purpose of 
characterizing the ligand-protein interactions, which would presumably be correlated 
with behavioral activity (Forrest, et al., 2007; Zhou, et al., 2009).  In the present study, 
mutations were chosen based on amino acids conserved at the same position in other NSS 
transporters, namely the dopamine transporter (DAT), the norepinephrine transporter 
(NET), and LeuT. 
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Figure 2: Partial sequence alignment of LeuT and hSERT highlighting protein similarities 
for transmembranes 9 and 10. Conserved residues are highlighted in blue, residues of 
similar charges are highlighted in magenta. Figure created and colored by Dr. Tammy 
Nolan. 
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Three-dimensional data derived from the LeuT-leucine cocrystal (Yamashita et al., 2005) 
provided a reliable template for MAT models, even though only 25% amino acid 
sequence identity and 45% similarity are observed (Beuming et al., 2006).  Importantly, 
LeuT and MATs apparently share the same mechanism of transport.  Crystallization of 
this bacterial MAT homolog has spawned the creation of 3D MAT molecular models that 
are predicting important residues for inhibitor binding.  Such models guide molecular 
pharmacological studies; a SERT residue predicted from the model to contribute to its 
functional properties can be mutated and pharmacologically characterized for changes in 
transport or inhibitor binding properties.  In spite of the functional importance of this 
transporter and its inhibitors, much remains unknown about the structural basis of 
inhibitor function at binding sites of the serotonin transporter. 
 
 
D. SERT binding of ligands 
 
It is assumed that a therapeutic with a novel scaffold could reduce affinity for extraneous 
targets, thereby decreasing unwanted side-effects.  In order to rationally create novel 
medications for disorders associated with SERT, it would be helpful to know how 
existing therapeutics operate at the molecular level.  Transporters must open and close to 
allow passage of ions and endogenous and/or exogenous ligands.  As mentioned above, 
substrate influx is accomplished by substrate binding when the external gate is open.  The 
internal gate opens when the external gate closes and the substrate can dissociate to the 
cytoplasmic region.  The internal gate can only be open when the external gate is closed, 
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and vice versa.  Multiple residues likely contribute to this conformational change of the 
protein in a concerted effort involving hydrophilic loops as well as the transmembrane 
domains.  The substitution of some residues may simply interrupt the infrastructure of the 
protein, but changing residues that play a role in substrate or ion recognition is likely to 
disrupt binding patterns and therefore disrupt the pharmacological profile of known 
inhibitors (Barker et al, 1998).  Based on previous characterization of the SERT and other 
NSS proteins, some transmembrane domains have been implicated as important 
participants in the formation of binding pockets.  TMs 1 – 10 of LeuT form the essential 
core.  This core would be a logical place to expect to find a substrate or inhibitor binding 
pocket or pockets.  The TM1 and TM6 domains have the highest density of conserved 
MAT residues.  TM11 and TM12 were found to be outside of the substrate/ion pore 
created with TMs 1-5 and TMs 6-10 (Yamashita et al., 2005).  A serine residue present in 
TM7 of the MATs serves as the Cl
- 
cofactor that stabilizes Na
+
 binding and thereby leads 
to the subsequent translocation of the substrate (Forrest et al., 2007).  In the LeuT crystal, 
its substrate (leucine) was found midway through the lipid bilayer in a pocket created by 
the unwound portions of TM1 and TM6.  Coincidentally, these unwound portions of 
TM1 and TM6 are also thought to act as pivots for the transporter’s conversion between 
the outward- and inward-facing conformations. 
 
In addition to the primary ligand binding pocket at the TM1 – TM6 midpoint, a 
secondary pocket in the MAT extracellular vestibule region has been implicated in 
substrate/inhibitor binding.  Unwinding of TM1 and TM6 exposes main chain carbonyl 
oxygen and nitrogen atoms that form a hydrogen bond to the substrate and the sodium 
 8 
 
ions.  The external gate is composed of one arm between TM1 and TM10 and another 
arm between TM3 and TM8, and binding of the substrate may be governed by the 
opening and closing of the gates, thereby regulating the binding of inhibitors.  The 
binding pockets for substrates and inhibitors may overlap (Andersen et al., 2009), or may 
be completely separate.  Tricyclic antidepressant (TCA) drugs have been shown to bind 
several angstroms above the primary substrate pocket in LeuT crystals.  LeuT-TCA 
cocrystals show a salt bridge formed by TM1 and TM10 (external gate strut) with a water 
molecule being displaced (Sinning et al., 2009).  TCAs have been thought to bind farther 
into the vestibule of SERT, causing a rotation of the inhibitor that disrupts the salt bridge 
between Arg104 (TM1) and Glu493 (TM10), opening the “aromatic lid” that covers the 
pore into the protein.  This would allow the ring system of TCAs to be situated between 
the two gates at the binding site.  TCAs and SSRIs were found to bind to dist inct regions 
of the vestibule and prevent substrate uptake by stabilizing the inward conformation 
(Zhou et al., 2009).   
 
A structural analog is a compound with a structure that is similar to that of another 
compound, but differing from it in a certain component. It can differ in one or more 
atoms, functional groups, or substructures, and replaced with other atoms, functional 
groups, or substructure.  A compound can be structurally related to the parent compound, 
but this similarity does not guarantee functional similarity. Analogs can have different 
physical, chemical, biochemical, or pharmacological properties than the parent 
compound. An analog could differ in selectivity for the protein or in ability to inhibit 
serotonin uptake as compared to the parent compound. They could also be created to 
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include a cross-linker or a photosensitive group to be used in additional experiments for 
characterizing the binding pockets. Analogs of known SERT inhibitors can be used and 
tested for SERT binding and to additionally characterize the binding pockets of the 
protein. In drug development, structural analogs of an initial lead compound can be tested 
as part of a structure-activity relationship study.  Lack of knowledge about the specific 
ligand-SERT interactions that lead to their clinical efficacy represents a problem for 
rationally developing novel therapeutics for SERT-associated disorders. 
 
 
E. Computational modeling 
 
The elucidation of the SERT 3D structure in the absence of X-ray crystal or NMR data 
can be addressed using comparative molecular modeling.  Comparative, or homology, 
modeling is based on the proposal that tertiary protein structures are more often 
conserved than amino acid sequences (Petrey and Honig, 2005).  Evolutionarily-related 
proteins can share comparable physicochemical properties and possess common 
structural and spatial similarities even if they diverge in their amino acid sequences. 
Protein structures are more conserved than protein amino acid sequences; therefore, the 
accuracy and usefulness of the models that can be obtained are positively correlated to 
the sequence similarity between the template and the target proteins (Pieper et al., 2002). 
Comparative modeling has been shown to be uncomplicated and typically accurate for 
proteins that share greater than 40% amino acid sequence identity (Hillisch et al., 2004; 
Petrey and Honig, 2005).  Proteins with less than 30% residue similarity increase the 
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complexity in creating a homology model, but such models have been successfully 
generated.  These models have guided the creation of other useful models, as well as 
helped in the virtual screening and pharmacological characterization of other proteins 
within the same superfamily (Surratt and Adams, 2005). 
 
The technique of homology modeling is used to generate atomic resolution 3D structures 
of proteins with unknown 3D structures (target), based primarily on alignment with one 
or more proteins of known 3D structure (templates) evolutionarily related to the target 
(Petrey and Honig, 2005).  In the absence of an experimentally determined structure, a 
comparative model can provide not only a starting point for experimentally validated 
research as was done in this study, but also an evolving representation of the target and 
other structurally-functionally related targets.  The four main steps in the process of 
creating a protein model are template selection, target-template alignment, model 
building, and model evaluation (Hillisch et al., 2004; Dunbrack, 2006).  For the SERT 
homology model used in this study, LeuT was chosen as the template based on the 
sequence similarities, which are partially shown in Figure 2.  Generation of a reliable 
computational model is critical for the accuracy of the predictions to be made from the 
model.  
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F. Virtual screening 
 
As verified via X-ray structures, similar ligands can bind in different conformations to the 
same class of protein (Davis et al., 2003).  A single protein structure is only useful to 
identify ligands for that particular conformational state (Carlson and McCammon, 2000). 
This can prove a challenge when virtually screening a homology model for new potential 
therapeutics.  These proteins often offer multiple binding modes as they shift to allow for 
the binding of a diverse array of substrates and inhibitors.  This potential for diverse 
compounds to bind to the SERT provides the opportunity to find novel inhibitors. 
 
Docking is a computational technique that assists in predicting the binding modes of 
ligands within the target protein pocket.  The orientation of a ligand within the binding 
pocket can be predicted by docking (Moustakas et al., 2006). Starting with a large pool of 
molecules, this digital database is used to evaluate the ability of unknown compounds to 
dock to the target protein.  This digital technique is an alternative to the time-consuming 
and expensive technique of experimental high throughput screening (HTS).  An 
advantage of this virtual screen is that one may use it to search only for drug-like 
candidates (Hristozov et al., 2007) and the goal is to find novel-scaffold “hit” compounds 
in silico with relevant biological and pharmacological activities.  As mentioned 
previously, a novel scaffold could reduce affinity for extraneous targets, something that 
has plagued SSRIs on the market. 
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Virtual screening and docking validation attempts to predict how a ligand may bind in the 
target protein.  Experimental pharmacology is necessary to probe how the compounds 
with high virtual binding scores bind to the target protein.  Once hit compounds are 
chosen, the purchase, based on price and availability, can be carried out and the 
pharmacological effects of the compounds can be tested experimentally (Evers et al., 
2005). The model can then be used as a guide for the position and/or structure of 
involved functional groups that may interact with an inhibitor (Figure 3). This method of 
verification can not only assist in the refinement of the model (in a trial-and-error 
approach of moving amino acid side chains or functional groups), but also in the 
identification of the SERT binding pocket(s).  Unfortunately, the actual percentage of 
compounds that emerge as hits from virtual screening are typically less than 1% (Bailey 
and Brown, 2001; Schneider and Bohm, 2002). Also, when X-ray structures are not 
known and homology models of the target protein are used for the virtual screening 
process, typically low micromolar (1-10 uM) activities of compounds are found (Anand 
et al., 2003).  Hit compounds of higher affinity to the target protein are more likely to be 
found when the template and the target share high sequence similarity.  
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Figure 3: 3D representation of residues predicted to comprise the binding pockets of 
SERT using Dr. Manepalli’s SERT model. Sertraline is colored as yellow within the 
vestibular pocket and serotonin is colored as magenta in the interior pocket. 
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G. Clinical Significance 
 
Major Depressive Disorder affects greater than 121 million people world-wide.  The 
economic cost of this disorder, through lost productivity and increased medical expenses, 
exceeds $83 billion each year.  Antidepressants represent the third-largest pharmaceutical 
category in the world.  Depression and its treatment are a large burden on the health care 
industry, as is the treatment of anxiety.  TCAs were the first generation of depression 
medications.  These include drugs with a tricyclic ring structure similar to clomipramine.  
These compounds resulted in severe side effects due to the lack of selectivity.   
 
Selective serotonin reuptake inhibitors (SSRIs) have more structural variations and are 
currently considered first for the amelioration of depression, and used for many other 
mood disorders including anxiety, obsessive-compulsive disorder, and post-traumatic 
stress disorder.  SSRIs selectively bind to the serotonin transporter (SERT), which is 
well-established as a therapeutic drug target for depression and anxiety.  The ability of 
SSRIs to inhibit neuronal serotonin reuptake, and ultimately lead to an increase in 
serotonin receptor activation, leads to their effectiveness. Although SSRIs are successful 
in treating multiple disorders, these drugs have disadvantages such as slow onset of 
action, sleep disruption, weight gain, and nausea (Moret et al, 2009).  During the first few 
weeks of SSRI use, more serotonin is available, but a downregulation of 5-HT2A 
postsynaptic receptors occurs, which decreases the possible activation of the postsynaptic 
neuron (Eison and Mullins, 1996).  The additional serotonin also activates presynaptic 
autoreceptors, which serve as feedback sensors for the cell.  Activation of the 
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autoreceptors will trigger a decrease in serotonin production and therefore a decrease in 
serotonin release. These neurophysiological adaptations to SSRI use make necessary 
multiple weeks of treatment prior to the behavioral benefits.  Also, the ligand-protein 
interactions that lead to the clinical efficacy of SSRIs remain unknown.  The SSRIs most 
often prescribed are compounds of diverse structure. Understanding the molecular actions 
of therapeutics at SERT would aid in the rational design of novel treatments for these 
mood disorders. 
 
The hypothesis of the presented study is: A computer-generated SERT model can guide 
structure-function studies on the protein and screen in silico small molecule libraries 
toward discovery of lead compound therapeutics of novel scaffold.  
 
The varied methods mentioned in this brief introduction, including the use of an in silico 
SERT model, mutagenesis, and virtual screening, can be used in conjunction with one 
another in order to determine the structure of SERT and find therapeutic inhibitors with 
novel structural scaffolds.  Structurally novel SERT inhibitors can be rationally designed 
to bind with higher affinity or selectivity for SERT over other MATs. Achieving 
selectivity for SERT would minimize the side effects seen in the older generation of 
antidepressants (tricyclic antidepressants) as well as in SSRIs.  Therefore, there is an 
urgent need for novel hSERT inhibitors with improved clinical characteristics.  A major 
goal of this research is to elucidate the structure of SERT and use this information to find 
or design new therapeutics for the treatment of serotonin-related disorders. 
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Methods 
CELL CULTURE 
A stably-transfected WT hSERT HEK cell line employed in the study was grown 
in DMEM media (with 10% fetal bovine serum, 10% penicillin/streptomycin, and 20 mM 
L-glutamine) at 37
o
C in 5% CO2 incubators.  Cells were grown as monolayers in 75 cm
2
 
flasks at 37˚С and 5% CO2 and subcultured twice a week or every 3 days.  For 
subculturing the cells, the exhausted media in the flask was aspirated and the confluent 
adherent cells were washed once with 10 ml HBSS.  To detach the hSERT HEK cells 
from the flask, 3 ml trypsin-EDTA was added and swirled to cover the cell monolayers, 
and then 2 ml of the trypsin-EDTA was removed, leaving 1 ml of the trypsin-EDTA in 
the flask.  When the cell monolayer was detached from the flask, 9 ml of complete media 
was added to the flask to inactivate the trypsin.  To remove the media containing trypsin-
EDTA, a 10 ml cell suspension was transferred into a 15 ml tube and centrifuged at 1000 
rpm for 3-4 minutes.  After removing the supernatant, the cell pellet was suspended with 
10 ml complete media, and 2 ml of the cell suspension was transferred into a new labeled 
flask containing 18 ml complete media.  The flask was tightly capped and then gently 
swirled to suspend the cells evenly.  The flask was placed in the incubator and the cells 
were allowed to grow until the next subculture. 
A stably-transfected WT hDAT N2A cell line employed in the study was kindly 
provided by Dr. Margaret E. Gnegy’s Laboratory (University of Michigan).  The hDAT 
N2A cells were similarly grown, except OPTI-MEM І media supplemented with 10% 
fetal bovine serum (FBS), 100 units/ml penicillin, 100 units/ml streptomycin and 100 
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μg/ml of G-418 was used.  For whole-cell experiments, one mL of the transfected cell 
suspension was distributed within 24 well plates and allowed to incubate until confluent.  
 
SITE-DIRECTED MUTAGENESIS AND CONSTRUCTION OF MUTANT 
PLASMIDS 
        The mutated fragments of WT hSERT were generated and amplified by the 
polymerase chain reaction (PCR) using a Quickchange kit.  The following single 
mutations were introduced into WT hSERT by Ms. Yurong Huang, formally of the 
Surratt lab: Lys490Thr, Glu494His, Glu494Thr, Trp103Ala, Val489Phe and Glu493Asp.  
The sequences of forward and reverse primers designed for Lys490Thr of hSERT were 
respectively: 5’-CATACTCCTCCAGCAGCGTCACCACGTAGGCCCCTC-3’ and 5’-
GAGGGGCCTACGTGTGACGCTGCTGGAGGAGTATG-3’.  The sequences of 
primers designed for Glu494Thr of SERT were: 5’-
GCGGGCCCCGTGGATACGTCTCCAGCAGCTTCAC-3’ and 5’-GTGAAGCTGC 
TGGAGACGTATGCCACGGGGCCCGC-3’.  The sequences of primers designed for 
Glu494His of SERT were: 5’-GCGGGCCCCGTGGATAATGCTCCAGCAGCTTCAC-
3’ and 5’-GTGAAGCTGCTGGAGCATTATGCCACGGGGCCCGC-3’.  The sequences 
of primers designed for Trp103Ala of SERT were: 5’-GACCTGG 
GCAATGTCGCGCGCTTCCCCTAC-3’ and 5’-
GTAGGGGAAGCGCGCGACATTGCCCAGGTC-3’.   The sequences of primers 
designed for Val489Phe of SERT were: 5’-
GAGGGGCCTACGTGTTCAAGCTGCTGGAGGAG-3’ and 5’-
CTCCTCCAGCAGCTTGAACACGTAGGCCCCTC-3’.  The sequences of primers 
 18 
 
designed for Glu493Asp of SERT were:  5’-
GTGGTGAAGCTGCTGGACGAGTATGCCACG-3’ and 5’-
CGTGGCATACTCGTCCAGCAGCTTCACCAC-3’.  The primers were synthesized 
with PAGE purification by Operon (Huntsville, AL).   WT hSERT in pcDNA3 vector 
was used as the template DNA.  The reaction tubes were prepared with 40 uL sterile 
water, 5 uL 10X Pfu reaction buffer, 1 uL WT SERT template (10 ng/uL), 1 uL Primer f 
(11 uM), 1 uL Primer r (11 uM), 1 uL dNTP, and 1 uL Pfu Turbo polymerase (2.5 U/uL).  
The reaction was set for 25 cycles with denaturation of the double stranded template 
DNA at 95˚С for 45 seconds, annealing of the primers to the single stranded DNA at 
55˚С for 45 seconds and extension of the new DNA strand at 72˚С for 2 minutes.  
Agarose gel electrophoresis was employed to confirm that PCR products were of 
appropriate size.   The PCR product was first transformed into MC1061 cells by the heat 
shock transfection method, followed by plating the cells on ampicillin supplemented agar 
petri plates and incubating at 37˚С for 16-18 hours.  Bacterial colonies were picked to 
inoculate in 5 ml of LB broth and the bacteria were allowed to grow at 37˚С for 16 hours.  
The supercoiled plasmid DNA was extracted using Stratagene mini-prep kits.  The size of 
the DNA was screened by agarose gel electrophoresis, and then the mutation-containing 
region was confirmed by DNA sequencing (University of Pittsburgh core facility).  After 
sequence confirmation, the DNA product containing the mutated region was further 
chosen to inoculate 200 ml of LB broth to produce large amounts of the cDNA plasmid 
of interest.  The concentration of the cDNA plasmid was assessed by measuring the 
absorbance at 260 and 280 nm.  Plasmid cDNA with a 260/280 ratio of no less than 1.70 
was considered pure enough for transient transfection of mammalian cells.  The entire 
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coding sequence of the mutant cDNA plasmid was confirmed by DNA sequencing not to 
have extraneous mutations.  
 
CELL TRANSFECTIONS 
Transient transfections of N2A cells were conducted via the modified calcium 
phosphate method (Graham and van der Eb, 1973).  The day before the transfection, cells 
were subcultured and incubated in 24-well tissue culture plates (uptake assay) or the 
150×10 mm cell culture dishes (ligand binding assay) at 37˚С and 5% CO2.  On the day 
of transfection, N2A cells were 30-40% confluent.  Four hours prior to transfection, the 
media in the wells was replaced with fresh complete media.  To begin the transfection, 
two sterilized tubes were prepared containing equal volumes of transfection reagents.  
Millipore water, plasmid DNA, 10X Tris-EDTA (TE) buffer pH 8.0 and 0.5 M CaCl2 
were added into the first tube and the concentration of plasmid DNA was diluted to be 
14.28 ng/µl.  The second tube contained 2X HBS buffer.  The contents of the first tube 
were added into the second tube dropwise with continuous gentle vortexing.  Fifty 
seconds after adding the last drop, a uniform suspension was performed by pipetting the 
mixture up and down, and the particle size of the DNA complexes was therefore reduced.  
One hundred µl of the above mixture was then added into each well and the plates were 
gently swirled to ensure uniform distribution.  After 16-18 hours, the media containing 
Ca
2+
 and unincorporated DNA was replaced with 1 ml fresh complete media.  The N2A 
cells transiently expressing hSERT or hSERT mutations were ready for pharmacological 
testing by the next day.  
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COMPETITION BINDING ASSAYS  
The cocaine analog [
125
I]-RTI-55 has been demonstrated to be a useful SERT 
ligand for the competition binding assays employed here (Boja et al., 1992; Mortensen et 
al., 2001; Henry et al., 2006b).  [
125
I]-RTI-55 inhibition binding assays performed with 
HEK cells stably expressing hSERT and N2A cells transiently expressing hSERT 
constructs were on 150 х 25 mm tissue culture-treated Petri plates.  For preparing the cell 
membrane, cell monolayers were washed 2 х 10 ml with ice-cold phosphate-buffered 
saline (PBS) and subsequently transferred to 15 ml centrifuge tubes.  Following low 
speed centrifugation, 700 х g, supernatant was aspirated and the cell pellet was 
resuspended in ice-cold TE buffer (50 mM Tris, pH 7.5, 1mM EDTA).  The suspension 
was subjected to high voltage ultrasonic treatment for 10 seconds to disrupt the intact 
cells.  Homogenate was transferred to cold 1.5 ml microcentrifuge tubes and centrifuged 
at 100,000 х g at 4˚C for 30 min (Sorvall Discovery M150 centrifuge).  Supernatant was 
aspirated, and the pellet was then resuspended in ice-cold binding buffer (50 mM Tris, 
pH 7.5, 100mM NaCl).  A portion of each sample was quantitated for protein content 
using the Bradford protein assay.  For further performing of the binding assays, [
125
I]RTI-
55 (0.1 nM final concentration), nonradioactive competitor (1 fM~1 µM final 
concentration), binding buffer, and membrane suspension were combined in 12 х 75 mm 
borosilicate glass tubes and  incubated at room temperature for 1 hour with gentle mixing 
(orbital shaker).  The mixtures were rapidly filtered through glass fiber filters (Schleicher 
and Schuell, Keene, NH) presoaked in 0.5% polyethylenimine solution (v/v).  The filters 
were washed twice with 5 ml cold 50 mM Tris buffer and transferred to the counting 
vials.  Incorporation of radioactivity was determined using a Beckman scintillation 
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counter.  Non-specific binding was determined by using 1 μM paroxetine.  Ki values 
were determined via nonlinear regression analysis with GraphPad Prism 5.0.  
 Whole-cell binding experiments used a stable HEK cell line expressing the 
serotonin transporter. Cells were plated as monolayers in 24-well plates. The cells were 
washed twice with 2 mL KRH buffer. [
3
H]-serotonin and increasing concentrations of the 
nonradiolabeled competitor is added in duplicate to the monolayer of HEK hSERT cells.  
The incubation proceeded for 15 minutes before washing the monolayer twice with 2 mL 
of KRH and 500 µL SDS.  Cells were then transferred to scintillation vials for 
determination of the amount of [
125
I]-RTI-55 able to compete with the nonradiolabeled 
inhibitor.  Nonspecific binding is determined by addition of 10 µM paroxetine.  The raw 
data will be of the specific activity (Ci/mmol) will be determined with GraphPad Prism 4 
software. 
Separate competition binding assays employed the cocaine analog [
3
H]-WIN 
35,428 as the radiotracer.  WT hDAT N2A cell monolayers, in 24-well plates, were 
washed 2 х 1 ml with KRH/AA buffer (25 mM HEPES, pH 7.3, 125 mM NaCl, 4.8 mM 
KCl, 1.3 mM CaCl2, 1.2 mM Mg2SO4, 1.2 mM KH2PO4, 5.6 mM glucose).  The cell 
monolayers were incubated with 500 μl of [3H]-WIN 35,428 (1 nM) and nonradioactive 
competitor (0.1 nM – 10 μM) for 15 minutes, followed by washing the cell monolayers 2 
х 1 ml with KRH/AA buffer. The non-specific binding was determined by using 10 μM 
mazindol as the blocker.  Cell monolayers were solubilized by incubating with 1 ml of 
1% SDS at room temperature for 1 hour with gentle shaking.  The cell lysates were 
transferred into scintillation vials containing 5 ml of ScintiSafe fluid and the incorporated 
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radioligand was determined by employing a liquid scintillation counter.   Ki values were 
analyzed with GraphPad Prism 5.0. 
 
[
3
H]-SEROTONIN UPTAKE INHIBITION ASSAYS 
        [
3
H]-serotonin uptake assays were performed with N2A cells transiently 
expressing WT hSERT or hSERT mutations or were performed with HEK cells stably 
expressing hSERT in 24-well plates.  For performing uptake assays, cell monolayers 
were washed 2 х 1 ml with KRH/AA buffer.  The cell monolayers were incubated with 
375 μl of KRH/AA buffer (total uptake) or 10 µM paroxetine (non-specific uptake) for 10 
minutes, followed by incubation with 125 μl of 10 nM [3H]-serotonin for an additional 5 
minutes.  Cell monolayers were washed 2 × 1 ml with KRH/AA buffer, and then 
solubilized by incubating in 1 ml of 1% SDS with gentle shaking at room temperature for 
at least 1 hour.  The cell lysates were transferred into scintillation vials containing 5 ml of 
ScintiSafe fluid, and the incorporated radioligand [
3
H]-serotonin was determined by 
employing a liquid scintillation counter. The non-specific uptake was determined by 
using 10 μM paroxetine if S-citalopram was the blocker or 10 μM S-citalopram if 
paroxetine was the blocker. The specific uptake was determined by the difference 
between total and non-specific uptake. 
 
[
3
H]-DOPAMINE UPTAKE INHIBITION ASSAYS 
All [
3
H]-dopamine uptake assays were performed similar to the [
3
H]-serotonin 
uptake assays except 10 nM [
3
H]-dopamine was used in place of [
3
H]-serotonin, and the 
cells were incubated with 375 μl of KRH/AA buffer and the inhibitor (0.1 nM~10 μM) 
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for 10 minutes, followed by incubation with 125 μl [3H]-dopamine for an additional 5 
minutes.  The non-specific uptake was determined by using 10 μM mazindol as the 
blocker. The IC50 values for [
3
H]-dopamine uptake inhibition were determined using 
GraphPad Prism 5.0.  
 
DATA ANALYSIS  
GraphPad Prism 5.0 was used to determine statistical significance using Student's 
T-test.  
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MATERIALS AND EQUIPMENT 
FACILITIES 
Laboratories- Room 456, 414, 408, 457 and 459, Mellon Hall of Science, Duquesne 
University 
 
MATERIALS  
Cell lines 
N2A (murine neuroblastoma) cells 
Dr.Margaret E. Gnegy’s laboratory, Department of Pharmacology, University of 
Michigan, MI 
 
hSERT HEK cells (HEK cells stably expressing human serotonin transporter) 
 
hDAT N2A cells (N2A cells stably expressing human dopamine transporter) 
Dr. Margaret E. Gnegy’s laboratory, University of Michigan, MI 
 
hNET HEK cells (N2A cells stably expressing human norepinephrine transporter) 
 
Chemicals and drugs 
[
3
H]-Dopamine (3, 4-[Ring-2, 5, 6-
3
H]-Dihydroxyphenylethylamine) 
Perkin Elmer, Foster City, CA 
 
[
3
H]-Citalopram     
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Perkin Elmer, Foster City, CA 
 
[
3
H]-Paroxetine    
Perkin Elmer, Foster City, CA 
 
[
3
H]-WIN 35,428   ([N-Methyl-
3
H]-WIN 35,428) 
Perkin Elmer, Foster City, CA 
 
[
3
H]-Serotonin     (5-[1, 2-3H(N)]-Hydroxytryptamine creatinine sulfate)  
Perkin Elmer, Foster City, CA 
 
[
125
I]-RTI-55   
Perkin Elmer, Foster City, CA 
 
Acetic acid 
Fisher Scientific, Pittsburgh, PA 
 
Agarose 
Invitrogen Corporation, Carlsbad, CA 
 
Ampicillin sodium salt 
Acros, Carlstadt, NJ 
 
 26 
 
Calcium chloride 
Sigma-Aldrich Corporation, St. Louis, MO 
        
       S-citalopram hydrochloride 
       Tocris Bioscience, Ellisville, MO 
       
Compressed carbon dioxide 
Air Products, Pittsburgh, PA 
 
D-(+)Glucose 
Sigma-Aldrich Corporation, St. Louis, MO 
 
Dimethylsulfoxide (DMSO) 
Sigma-Aldrich Corporation, St. Louis, MO 
 
Dulbecco’s Modified Eagle Medium (DMEM) 
Hyclone, Logan, UT 
 
dNTP mix 
Stratagene, La Jolla, CA 
 
EDTA 
Sigma-Aldrich Co., St. Louis, MO 
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      Ethanol, 200 proof 
PharmacoProduct Inc., Brookfield, CT 
 
Ethanol, HPLC grade 
ACROS, Fair Lawn, NJ 
 
Ethidium bromide 
Fisher Scientific, Pittsburgh, PA 
 
Fetal bovine serum 
Hyclone, Logan, UT 
 
G-418 sulfate 
Clontech Laboratories Inc., Mountain View, CA 
 
L-Glutamine 
Invitrogen, Carlsbad, CA 
 
HEPES free acid 
MP Biomedicals Inc., Solon, OH 
 
HBSS/Modified 
Hyclone, Logan, UT 
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Isopropanol (DNase, RNase and protease free) 
Fisher Scientific, Pittsburgh, PA 
 
LB agar 
Fisher Scientific, Pittsburgh, PA 
 
LB broth 
Fisher Scientific, Pittsburgh, PA 
 
Methanol, HPLC grade 
Fisher Scientific, Pittsburgh, PA 
 
MC1061 cells 
Invitrogen, Carlsbad, CA 
 
Opti-MEM 1 
Invitrogen, Carlbad, CA 
 
Paroxetine hydrochloride 
Toronto Research Chemicals Inc., North York, ON Canada 
 
Penicillin-Streptomycin 
Gibco-BRL, Grand Island, NY 
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Polymerase, Pfu Turbo 
Stratagene, La Jolla, CA 
 
Potassium chloride 
Sigma-Aldrich Co., St. Louis, MO 
 
Potassium phosphate, monobasic 
Sigma-Aldrich Co., St. Louis, MO 
 
Custom oligonucleotide primers 
Operon, Huntsville, AL 
 
RNase A (DNase free) 
Fisher Scientific, Pittsburgh, PA 
 
SOC media 
Invitrogen, Carlsbad, CA 
 
ScintiSafe scintillation fluid 
Fisher Scientific, Pittsburgh, PA 
 
Sodium chloride 
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Sigma-Aldrich Co., St. Louis, MO 
 
Sodium hydroxide 
Fisher Scientific, Pittsburgh, PA 
 
Sodium hydroxide solution 
Fisher Scientific, Pittsburgh, PA 
 
Sodium lauryl sulfate 
Sigma-Aldrich Co., St. Louis, MO 
 
Tris-EDTA buffer (DNase, RNase and protease free) 
Acros, Carlstadt, NJ 
 
Trizma buffer, free base 
Fisher Scientific, Pittsburgh, PA 
 
Tris buffer, HCl salt 
Sigma-Aldrich Co., St. Louis, MO 
 
Trypsin-EDTA 10X 
Gibco-BRL, Grand Island, NY 
 
 31 
 
Tropolone 
Sigma-Aldrich Co., St. Louis, MO 
 
Kits 
Gel extraction kit 
Qiagen Inc., Valencia, CA 
 
PCR purification kit 
Qiagen Inc.,Valencia, CA 
 
Plasmid miniprep kit 
Stratagene, La Jolla, CA 
 
Plasmid purification kit 
Qiagen Inc.,Valencia, CA 
 
Quickchange Mutagenesis kit 
Stratagene, La Jolla, CA 
 
Other Materials 
Cell culture flasks, 75 cm
2 
Corning Inc., Teterboro, NY 
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Cell culture grade water 
Hyclone, Logan, UT 
 
Cell culture plates (10, 25 cm) 
Fisher Scientific, Pittsburgh, PA 
 
Centrifuge tube, 15 ml 
Corning Inc., Horseheads, NY 
 
Centrifuge vials, 1.5 ml 
Corning Inc., Horseheads, NY 
 
Culture tubes, disposable 
Fisher Scientific, Pittsburgh, PA 
 
Falcon tubes, 14 ml 
Fisher Scientific, Pittsburgh, PA 
 
Falcon tubes, 50 ml 
Fisher Scientific, Pittsburgh, PA 
 
Filter unit, sterile 
Millipore, Billerica, MA 
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Eppendorf microcentrifuge tubes, 1.5 ml 
Fisher Scientific, Pittsburgh, PA 
 
Parafilm 
Fisher Scientific, Pittsburgh, PA 
 
Pasteur pipettes, disposable 
Fisher Scientific, Pittsburgh, PA 
 
Pipette tips, disposable Redi-Tips TM (1, 10, 200, 1000 µl) 
Fisher Scientific, Pittsburgh, PA 
 
Polaroid film 
Fisher Scientific, Pittsburgh, PA 
 
Polypropylene tubes 
Fisher Scientific, Pittsburgh, PA 
 
Respirator 
Fisher Scientific, Pittsburgh, PA 
 
Scintillation vials 
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Fisher Scientific, Pittsburgh, PA 
 
Serological pipettes, sterile disposable (5, 10, 25 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Syringes, sterile (10 ml) 
Fisher Scientific, Pittsburgh, PA 
 
Thermowell PCR tubes 
Corning,  Horseheads, NY 
 
Tissue culture plates, sterile (6 well, 24 well) 
Fisher Scientific, Pittsburgh, PA 
Sarstedt Inc., Newton, NC 
 
EQUIPMENT 
Analytical balance 
Mettler Toledo Inc., Columbus, OH 
 
Cell culture incubator 
Forma Scientific, Worcester, MA 
 
Centrifuge, Model 228 
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Fisher Scientific, Pittsburgh, PA 
 
Refrigerated tabletop centrifuge, Model 5810R 
Eppendorf Scientific, Hauppauge, NY 
 
Eppendorf dispenser (50 ml) 
Brinkmann Instruments Inc., Hauppauge, NY 
 
Electrophoresis power supply 
Life Technologies Inc., Gaithersburg, MD 
 
Horizontal gel electrophoresis system 
Life Technologies Inc., Gaithersburg, MD 
 
Isotemp incubator 
Fisher Scientific, Pittsburgh, PA 
 
Lab freezers and refrigerators 
Forma Scientific, Worcester, MA 
 
Liquid nitrogen tank 
Department of Chemistry and Biochemisty, Duquesne University 
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Liquid Scintillation Analyzer 
Packard Instruments, Meriden, CT 
 
Millipore Milli-Q ultrapure water system 
Millipore, Billerica, MA 
 
Mixer 37600 
Thermolyne Corporation, Duqubue, IA 
 
NapFLOW Laminar air flow unit 
Fisher Scientific, Pittsburgh, PA 
 
ORBIT Shaker 
Lab-line Instruments Inc., Melrose Park, IL 
 
PCR Mastercycler 
Eppendorf  Scientific, Hauppauge, NY 
 
pH Meter AB15 
Fisher Scientific, Pittsburgh, PA 
 
Pipet-aid 
Drummond Scientific Co., Broomall, PA 
 37 
 
 
Pipetman (P-2, P-10, P-20, P-100, P-200, P-1000) 
Mettler Toledo Company, Woburn, MA 
 
Polaroid Gelcam 
Polaroid Corporation, Cambridge, MA 
 
Universal vacuum system UVS 400 
Savant Instrument Inc., Holbrook, NY 
 
UV transilluminator M-26 
UVP Inc., Upland, CA 
 
UV-visible spectrophotometer DU 530 
Beckman Instruments Inc., Fullerton, CA 
 
Vacuum pressure pump 
Barnant Co., Lake Barrington, IL 
 
Vertex-2 Genie vortexer 
Scientific Industries Inc., Bohemia, NY 
 
Water bath, 180 series 
 38 
 
Precision Scientific, Winchester, VA 
 
Water bath, Iso TEMP 205 
Fisher Scientific, Pittsburgh, PA 
 
Microbalance 
Denver Instruments Co., Denver, CO 
 
Sorvall ultra centrifuge 
Thermo Fisher Scientific, Asheville, NC 28806 
 
COMPUTER SOFTWARE 
Adobe Acrobat Reader 7.0 
Adobe Systems Inc., San Jose, CA 
 
Adobe Acrobat Writer  
Adobe Systems Inc., San Jose, CA 
 
ChemDraw Ultra 11.0 
CambridgeSoft Corporation, Cambridge, MA 
 
GraphPad Prism 5.0 
GraphPad Software, San Diego, CA 
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Microsoft Office Word & Excel 2007 
Microsoft Corporation, Seattle, WA 
 
Molecular Operating Environment 2005.06/2007.09 
      Chemical Computing Group, Montreal, Canada 
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Results 
Aim 1 Results 
 
 
Aim 1 was to characterize SERT inhibitor binding sites using pharmacological testing of 
known inhibitors and analogs.  Analogs of known SERT inhibitors were tested for 
binding affinities in HEK cells stably expressing hSERT.  These analogs were created by 
the laboratory of Dr. David Lapinsky in an attempt to elucidate contacts made within the 
proposed binding pocket of the protein. The analogs were derived from 6-nitroquipazine, 
citalopram, fluoxetine, or a novel compound that used a fusion of 6-nitroquiupazine 
thought to contribute to neurogenesis (MacMillan et al. 2011). The parent compounds 
were chosen due to their known binding and specificity to SERT.  
 
The 6-nitroquipazine analogs were coded SADU 2-172 and SADU 2-179. The 
norfluoxetine analogs were coded DJLDU 3-104, 3-114, and 3-126. The citalopram 
compounds were coded NYDU 2-58, 2-63, 2-129, and 2-131. The fluoxetine analogs 
were coded NYDU 2-92 and 2-103. The neurogenesis compounds were coded SADU 3-
158 and 3-162. As shown in Table 1, most of the analogs, whether the changes were 
made to add a specific functional group, a cross-linker, or a radioisotope, showed 
differences in binding affinities but were still within the nanomolar range when compared 
to the parent compounds.  
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COMPOUND 
hSERT Ki 
(nM) 
6-nitroquipazine (SADU 2-172) 0.12 
SADU 2-179 124.7 
Norfluoxetine (SADU 2-191) 26 
DJLDU 3-104 102 
DJLDU 3-114 65.7 
DJLDU 3-126 724.3 
Citalopram 4.4 
NYDU 2-58 1.46 
NYDU 2-63 4.3 
NYDU 2-129 <1 
NYDU 2-131 6.7 
Fluoxetine (SADU 3-89) 4.4 
NYDU-2-92 161.3 
NYDU 2-103 771 
P7C3 (MacMillan Neurogenesis) N/A 
SADU 3-158 11.13 
SADU 3-162 4.74 
 
Table 1: Binding affinities of SERT inhibitors and analogs at HEK cells stably expressing 
hSERT. Compounds are color-coded to group parent compounds with analogs.  
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For consistency in a laboratory setting, it is important to standardize the conditions for 
experiments.  These conditions include the amount of protein used in a ligand-protein 
binding experiment.  In order to standardize the conditions for SERT membrane 
pharmacology, optimization experiments were carried out via saturation binding of 
cocaine or clomipramine, a TCA, binding.  Drug preincubation time was altered with no 
effect on hSERT binding.  Alternatively, the dilution of the membrane solution, which 
was done using membrane binding buffer, made a difference in the final Ki values 
obtained from the saturation binding assays (Figure 4).  This difference is important for 
consistency of current and future experiments, as it alters the level of protein available to 
bind to the available ligand.  As the dilution of 1/16 resulted in affinity values closest to 
reported clomipramine values of 0.3 nM (Goodman & Gilman, 2011), this was chosen as 
the optimized membrane dilution for the binding assay method. 
  
 43 
 
 
 
Figure 4: hSERT HEK293 membrane concentration optimization via saturation binding 
of cocaine or clomipramine. 
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Aim 2 Results 
 
Aim 2 was to use a SERT model to identify logical mutagenesis targets for in vitro 
characterization. Competition binding assays and uptake assays used N2A cells 
transiently transfected with a cDNA encoding the wildtype (WT) or mutant SERT 
protein.  These assays measured binding affinity or [3H]-serotonin uptake inhibition 
potency (SUIP) of established SERT ligands at each SERT mutant relative to that of WT 
SERT.  SERT mutants created by Yurong Huang were W103A, V489F, K490T, E493D, 
E494H, and E494T.  Naïve N2A cells were used as the negative control. Cells transfected 
with a SERT mutation may show a change in ligand affinity. A decrease or elimination of 
ligand affinity for a mutated SERT protein would indicate an important binding role for 
the substituted amino acid.  A decrease in function due to a change in a specific amino 
acid could suggest the location of a binding pocket, but it could also simply imply the 
amino acids importance in the structural configuration of the SERT protein.  
 
Inhibitor binding screening by WT SERT and mutants shows significant increase in 
radioligand binding by W103A mutant 
Screening of binding affinities at WT SERT and the mutants transiently transfected into 
N2A cells were done in order to evaluate changes to their ability to bind known 
inhibitors. As shown in Figure 5, [
125
I]-RTI-55 binding to W103A was significantly 
increased as compared to [
125
I]-RTI-55 binding at WT SERT.  
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Uptake inhibitor screening at WT or mutant SERT shows a significant decrease in 
[
3
H]-serotonin uptake by W103A, V489F, K490T, E494H, and E494T mutants 
Screening of uptake capacities for WT SERT and the mutants transiently transfected into 
N2A cells were done in order to evaluate potential changes in transporter function.  As 
shown in Figure 5, a decrease in [
3
H]-serotonin uptake was seen at W103A, V489F, 
K490T, E494H, and E494T, but not at E493D.  
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Figure 5: Screening for inhibitor binding and substrate uptake at hSERT mutants 
transiently expressed in N2A neuroblastoma cells. *p<0.05, **p<0.01. 
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Binding and uptake assays were performed using N2A cells transiently transfected with 
WT SERT or a mutated construct.  Non-radioactive RTI-55, citalopram, sertraline and 
cocaine were used in the assays as SERT inhibition competitors. [
125
I]-RTI-55 was used 
as the radioactive competitor in the binding experiments, and [
3
H]-serotonin was used in 
the uptake inhibition experiments.  Binding and uptake results with the mutants are 
presented in Table 2. 
 
W103A mutation had no effect on binding affinities, but increased uptake inhibition 
of citalopram 
Although the inhibitor binding screening only showed a significant difference between 
WT SERT and W103A (Figure 5), no changes occurred for any of the inhibitor binding 
affinities with W103A (Table 2). SSRI serotonin uptake inhibition potency increased as 
much as 6-fold with the TM1 W103A mutation. Net specific [
3
H]-serotonin uptake at 
W103A fell approximately 2-fold even though Bmax value for [
125
I]-RTI-55 saturation 
binding was not significantly affected.   
 
V489F mutation increased binding affinity to RTI-55, but decreased to cocaine, and 
increased uptake inhibition of citalopram 
Affinity for the cocaine analog RTI-55 increased 2-fold at the V489F mutant, but cocaine 
binding affinity decreased by 2-fold. Based on the structural differences between cocaine 
and its analog RTI-55, it can be suggested that the TM10 V489 residue may be in the 
vicinity of the C-3 tropane substituent of each drug.  Citalopram but not sertraline 
potency increased 2-fold with the V489F substitution. 
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K490T mutation increased binding affinity to RTI-55 
Affinity for the cocaine analog RTI-55 increased 2-fold at the V489F and K490T 
mutants.  Binding affinities to citalopram, sertraline, and cocaine were unaffected with 
the mutation, as well as the uptake capacities. 
 
E493D mutation decreased binding affinity to citalopram, sertraline, and cocaine, 
and decreased uptake inhibition of citalopram and sertraline. 
Citalopram binding affinity decreased 3-fold and sertraline affinity decreased 7-fold with 
the conservative E493D substitution. Although SSRI serotonin uptake inhibition potency 
increased as much as 6-fold with the TM1 W103A mutation, potency decreased 6-fold at 
the TM10 E493D mutant.   
 
E494H and E494T mutations decreased binding affinity to citalopram, and E494H 
decreased uptake inhibition of citalopram 
Citalopram binding affinity decreased 3-fold at E494H and by over 2-fold at E494T, but 
citalopram potency decreased 3-fold only at E494H, not at the charge-neutral E494T 
substitution.  Interestingly, sertraline affinity decreased 7-fold with the conservative E493 
substitution but was unaffected by the E494 mutations.  Because the E493 and E494 side 
chains are expected to diverge in space, loss of one glutamate side chain should not be 
compensated for by the presence of the other. Net specific [
3
H]-serotonin uptake at both 
E494 SERT mutants fell approximately 2-fold even though Bmax values for [
125
I]-RTI-55 
saturation binding were not significantly affected.  This phenomenon also occurred with 
the W103A mutant. 
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Table 2. Binding affinities & uptake inhibition potencies of SERT inhibitors at N2A 
neuroblastoma cells transiently expressing wildtype or mutant SERT proteins. *p<0.05, 
**p<0.01 vs WT. This table, minus the sertraline data, first appeared in the thesis of 
Yurong Huang, 2011. Some boxes are bold to highlight significant differences of binding 
or uptake when compared to WT results. 
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The pharmacological data shown in Table 2 suggest that when mutated singly, no one of 
the five SERT vestibular pocket residues surveyed is critical for high affinity binding of 
cocaine or the two SSRIs tested. These results are consistent with similar vestibular 
pocket SERT mutants (Anderson, 2009). These results were presented at the College on 
Problems of Drug Dependence conference (Miami, FL, 2011).  
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Aim 3 Results 
 
Aim 3 was to identify compounds with new structural scaffolds that bind to SERT. One-
point binding assays were performed using HEK cells expressing hSERT with fourteen of 
the top hit compounds (LM series) from the SERT model created by Dr. Martin Indarte 
(referred to as the MI SERT model). [
125
I]-RTI-55 was used as the radioactive competitor 
in the binding experiments. One-point binding assays using clomipramine was performed 
as positive control and buffer as negative control and total [
125
I]-RTI-55 binding. Results 
are presented as the percentage of competing radioligand binding with the hit compound. 
 
Hit compounds from MI SERT model did not inhibit [
125
I]-RTI-55 binding 
As seen collectively in Figure 6, none of the compounds screened as “hits” from the MI 
model inhibited [
125
I]-RTI-55 binding at SERT more than the arbitrarily-set threshold of 
50%.  This threshold was set as a standard guidepost based on the high concentration of 
drug (10μM) used to compete with [125I]-RTI-55 binding.  
 
Using the in silico model created by Dr. Sankar Manepalli (referred to as the SM SERT 
model), two sets of compounds were chosen for pharmacological testing.  The first set, 
SM, were higher ranking in silico than the MS set, and tested first.  One-point binding 
assays were performed using HEK cells expressing hSERT, hDAT, or hNET with the hit 
compounds from the SM series from the MI SERT model. [
125
I]-RTI-55 was used as the 
radioactive competitor in the binding experiments. Results are presented as the 
percentage of competing radioligand binding with the hit compound. 
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Figure 6: One-point binding of compounds in LM series to SERT 
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Figure 7: One-point binding of compounds in SM series to SERT 
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Hit compounds from SM series of SM SERT model did not inhibit [
125
I]-RTI-55 
binding at hNET 
A set of hit compounds screened at the SM SERT model was acquired and 
pharmacologically tested in one-point binding assays at hNET.  As seen collectively in 
Figure 7, none of the SM series compounds screened as “hits” from the SM model  
significantly inhibited [
125
I]-RTI-55 binding at HEK cells expressing hNET. 
 
One compound from SM model inhibited [
125
I]-RTI-55 binding at hDAT 
A set of hit compounds screened at the SM SERT model was acquired and 
pharmacologically tested in one-point binding assays at hDAT.  Nine of the ten 
compounds showed no significant binding affinity to HEK cells expressing hDAT.  
Although SM14 displayed no significant binding to hSERT, it appeared to inhibit [
125
I]-
RTI-55 binding to hDAT by 40%. Binding and uptake assays were completed and 
established an average Ki of 15.6 ± 2.4 μM and IC50 of 10.5 ± 4.6 μM (Figure 8). 
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Figure 8: Saturation binding and uptake of VS hit compound SM14 at hDAT HEK293 
cells. 
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Two compounds from SM model inhibited [
125
I]-RTI-55 binding at SERT 
A set of hit compounds screened at the SM SERT model was acquired and 
pharmacologically tested in one-point binding assays using HEK cell expressing hSERT.  
Two of the compounds screened using the SM model from the SM series, coded SM10 
and SM11, were found to have selective affinity for SERT over the dopamine transporter 
and norephinephrine transporter (Figure 7). The structures of these two compounds are 
seen in Figure 9. 
 
SM10 and SM11 were used in a saturation binding experiment for [
125
I]-RTI-55 
inhibition. SM10 was found to have an inhibition constant (Ki) equal to 38 ± 17 μM. The 
Ki value for SM11 was found to be 17 ± 7 μM (Figure 9).  
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Figure 9: Structures of two VS hit compounds showing affinity for SERT. Reprinted with 
permission from Manepalli, S., Geffert, L.M., Surratt, C.K., Madura, J.D. (2011). 
Discovery of novel selective serotonin reuptake inhibitors through development of a 
protein-based pharmacophore. J Chem Information and Modeling. 51; 2417-2426. 
Copyright 2011 American Chemical Society. 
 
  
SM-10 
Ki = 38 ± 17 μM 
SM-11 
Ki = 17 ± 7 μM 
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Figure 10: Saturation binding of VS hit compounds SM10 (closed circles) and SM11 
(open circles) at hSERT HEK293 cells.  Reprinted with permission from Manepalli, S., 
Geffert, L.M., Surratt, C.K., Madura, J.D. (2011). Discovery of novel selective serotonin 
reuptake inhibitors through development of a protein-based pharmacophore. J Chem 
Information and Modeling. 51; 2417-2426. Copyright 2011 American Chemical Society. 
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These results were published in the Journal of Chemical Information and Modeling 
(Manepalli, et al., 2011). 
 
Second set of hit compounds from SM SERT model did not inhibit [
125
I]-RTI-55 
binding 
A second set of hit compounds from the SM SERT model received lower ranking scores. 
The compounds were acquired and pharmacologically tested in one-point binding assays 
at hSERT.  As seen collectively in Figure 11, none of the MS series compounds screened 
as “hits” from the SM model inhibited [125I]-RTI-55 binding at SERT more than the 
arbitrarily-set threshold of 50%.  
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Figure 11: One-point binding of compounds in MS series to SERT  
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Discussion 
 
 
The SERT and other monoamine transporters have not yet been crystallized, but 
membrane protein structures can be studied using a variety of techniques.  Developing a 
computation model of the serotonin transporter (SERT) has been important for the 
modeling field and for the monoamine field.  A model can be an important tool for the 
molecular dissection of certain structure function activities or ligand-protein interactions.  
A useful model opens up new possibilities for the development of possible new 
antidepressants as well as prepare the field for the creation and testing of models of other 
proteins which are not crystallized as of yet.  This project demonstrates how an in silico 
model can be used in the pharmacological sciences and have applications for medicinal 
chemistry.  The aims fulfilled in this study became a possibility when the bacterial 
leucine transporter (LeuT), which shares with the SERT 25% identity and 45% similarity 
(Figure 2) at the amino acid sequence level (Beuming et al., 2006), was crystallized 
(Yamashita et al., 2005).  Moreover, based on the sequence similarities, LeuT is thought 
to have the same mechanism of transport as SERT.  This project also provides an 
innovative perspective into the interactions of monoamine transporters and inhibitors, 
which can support therapeutic development for disease states associated with SERT, such 
as depression and anxiety.  
 
As shown in Table 1, most of the analogs created by the laboratory of Dr. David 
Lapinsky, whether the changes were made to add a specific functional group, a cross-
linker, or a radioisotope, showed only modest differences in binding affinities when 
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compared to the parent compounds.  The pharmacologic similarities between the parent 
drugs and their analogs are encouraging, suggesting physiologic relevance of the latter as 
surrogates.  Although the results are not able to predict functionality, the ability of the 
analogs to bind to SERT is a positive advancement toward the development of novel 
therapeutics. 
 
A known SERT compound, 6-nitroquipazine, and an analog coded SADU 2-179 were 
tested at hSERT.  The analog represents a potential photoaffinity ligand.  The affinity of 
the analog for hSERT, albeit high in the nanomolar range, decreased when compared to 
the parent compound. This change can be attributed to the additional functional group 
added to the analog, which may be offering a small amount of steric hindrance to binding 
in the SERT pocket. 
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Figure 12: Structure of 6-nitroquipazine and one analog tested at hSERT. 
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The norfluoxetine analogs were coded DJLDU 3-104, 3-114, and 3-126. DJLDU 3-104 
represents racemic norfluoxetine (Figure 13).  DJLDU 3-114 and DJLDU 3-126 represent 
the S- and R-enantiomer of norfluoxetine respectively.  The affinities of DJLDU 3-104 
and DJLDU 3-144 were similar to the parent compound, suggesting the enantiomers are 
likely binding in the same binding pocket.  The R-enantiomer, DJLDU 3-126, displayed a 
lower affinity than the S-enantiomer. This suggests that the structural difference between 
the analogs allows for either a different binding mode or orientation in the SERT 
inhibitor pocket.  In this way, the use of norfluoxetine analogs can assist in probing 
biding sites.  The structural differences, along with their binding results, could indicate 
the protein-ligand interactions which are occurring in the proposed binding pocket. 
  
 65 
 
 
 
 
 
 
Figure 13: Structures of norfluoxetine (SADU 2-191) and three analogs tested at hSERT. 
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The citalopram compounds were coded NYDU 2-58, 2-63, 2-129, and 2-131. Citalopram 
is a compound with a hSERT binding affinity of 4.4 nM.  It is not surprising that the 
analogs were found to have high binding affinities because their parent compound, with a 
similar structure, also has a high binding affinity.  NYDU 2-58 represents citalopram 
derivatized with an acetophenone photoreactive group and a terminal alkyne clickable 
handle (Figure 14).  Clickable handles are a useful way to connect a new structural 
addition to a compound using a single chemical reaction. NYDU 2-63 also represents 
citalopram with a terminal alkyne clickable handle, but has a benzophenone 
photoreactive group. NYDU2-129 and 2-131 are both enantiomerically pure S-citalopram 
clickable photoprobes.  NYDU 2-131 was tested to see if the bulky benzophenone off of 
the nitrogen was tolerable for SERT binding.  The structural differences between 
citalopram and its analogs in addition to the binding results, suggest that different binding 
modes could be occurring for the analogs in the SERT inhibitor binding pocket.  In this 
way, the pharmacological testing of citalopram analogs can assist in probing biding sites 
and indicate changes to potentially improve on the parent compound. 
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Figure 14: Structures of two citalopram analogs tested at hSERT. 
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The fluoxetine analogs were coded NYDU 2-92 and 2-103.  Both of these compounds 
represent racemic fluoxetine derivatized with a linker, a photoreactive benzophenone, and 
a clickable propargyl ether/alkyne handle.  The affinity difference between the two 
analogs could be due to the single structural difference of a methyl group exchanged for 
hydrogen (Figure 15).  Although the fluoxetine analogs did not show improved binding 
affinity for SERT when compared to the parent compound, the results still aid in probing 
the proposed binding site and were created to add structures, including the linker, 
photoreactive benzophenone, and the clickable alkyne handle, to the parent compound for 
purification and detection.  In conclusion, the pharmacological testing of the fluoxetine 
analogs can indicate protein-ligand interactions in the binding pocket to perhaps be a 
hydrophobic pocket with favorable interactions near the methyl group of NYDU 2-92.   
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Figure 15: Structures of racemic fluoxetine (SADU 3-89) and two analogs tested at 
hSERT. 
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Chronic antidepressant treatment has been shown to increase cell proliferation, increase 
neuronal survival, and reverse the stress-induced decrease of hippocampal neurogenesis 
(Alonso et al., 2004).  The ability to increase hippocampal neurogenesis is a common 
feature of both SSRIs and TCAs (Malberg et al., 2000). It is suggested that hippocampal 
neurogenesis might be a major factor in the action of antidepressants.  The neurogenic 
compounds were coded SADU 3-158 and 3-162. SADU 3-162 is a P7C3 analog with 
fusion of 6-nitroquipazine.  These analogs were created from a parent compound (P7C3) 
that was found to be proneurogenic and neuroprotective (MacMillan et al., 2011).  Unlike 
some antidepressants that have been reported to enhance neurogenesis after two or three 
weeks of treatment, P7C3 effects neurogenesis within days of administration.  The 
molecular target of the parent compound is unknown, but the high affinity of compounds 
SADU 3-158 and 3-162 for hSERT would also make these good candidates for 
behavioral testing.  Multiple tests are commonly used in the field to test the 
antidepressant properties of compounds, including the tail suspension test, the forced 
swim test, and the novelty-induced hypophagia test (Talbot, et al., 2010). 
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Figure 16: Structure of Proneurogenic compound P7C3 (MacMillan et al. 2011) and 
analogs created by Dr. David Lapinsky.  Analogs were tested at hSERT. 
  
P7C3 
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In silico models have guided numerous site-directed mutagenesis studies for the purpose 
of characterizing the ligand-SERT protein interaction (Forrest et al., 2007; Zhou et al., 
2009).  The importance of specific residues for activity of the transporter can be 
established using a stable serotonergic cell line and pharmacological assays (Kaufmann et 
al., 2009).  Therefore, the functional significance of different drugs at the transporter site 
can be predicted using the virtual model of SERT as a rational starting point.  
Mutagenesis allows a focus on a particular amino acid or group of amino acids to assess 
their contribution to structure and functional properties, such as binding and uptake.  
Some studies utilizing in silico models have found results consistent with mutagenesis 
and consistent with the use of pharmacological methods (Andersen et al., 2009; Barker et 
al., 1998; Beuming et al., 2008).  No particular amino acid or sequence has been found to 
be characteristic of inhibitor binding sites.  
 
Our study aimed to characterize the SERT inhibitor binding sites using pharmacological 
testing of known inhibitors with rationally-designed SERT mutants.  Ms. Yurong Huang, 
formerly of the Surratt lab, used in silico SERT models to guide selection and creation of 
the mutants (Figures 3).  The importance of the replaced amino acid was determined via 
binding and uptake assays with the mutants transiently expressed in naïve N2A cells. 
 
SERT mutants created and assessed for binding and uptake capacity were W103A, 
V489F, K490T, E493D, E494H, and E494T. These residues were implicated in silico as 
components of a SERT binding pocket.   W103A is found in the first transmembrane 
domain (TM1) of the SERT protein, while the other mutants are found in the tenth 
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transmembrane domain (TM10).  These particular amino acids were chosen for mutation 
based on evidence for not only a primary binding pocket for the substrate (interior), but 
also for a secondary pocket in the vestibular region that may be responsible for substrate 
and inhibitor binding and overlap between the two pockets (Andersen et al, 2009). The 
unwinding of TM1 and TM6 exposes main chain carbonyl oxygen and nitrogen atoms, 
which form a hydrogen bond to the substrate and the sodium ions. The external gate is 
composed of one arm between TM1 and TM10 and another arm between TM3 and TM8, 
and binding of the substrate may be governed by the opening and closing of the gate, 
thereby regulating the binding of inhibitors. If a mutant shows impaired SERT inhibitor 
binding, it would be consistent with the idea that the endogenous amino acid plays a role 
in the binding process and would be partial confirmation that the binding pocket was 
identified.  Co-crystals of LeuT with a bound TCA show a salt bridge formed by TM1 
and TM10 with a water molecule being displaced (Sinning et al, 2009). TCAs have been 
thought to bind farther into the vestibule of SERT, causing a rotation of the inhibitor, 
which would disrupt the salt bridge between Arg104 and Glu493. Further information on 
the residue in question can be gained by identifying which amino acids restore function at 
that position (Henry et al, 2005).  The discrimination of the drug binding site will aid in 
the search for novel SERT ligands with high affinity and specificity using in silico 
models of SERT. 
 
Screening of binding affinities at WT SERT and the mutants transiently transfected into 
N2A cells were done in order to evaluate potential changes to their ability to bind known 
inhibitors. Our results of an inhibitor binding screening at WT SERT and the mutants 
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demonstrated a significant increase at W103A compared to WT SERT, but no change 
was seen in binding affinities of the other mutants. Screening of uptake capacities for WT 
SERT and the mutants transiently transfected into N2A cells were done in order to 
evaluate potential changes in transporter function.  Our results of substrate uptake 
screening at WT SERT and the mutants demonstrated a significant decrease in [
3
H]-
serotonin uptake at W103A, V489F, K490T, E494H, and E494T. This substrate uptake 
decrease was not seen at the E494D mutation. Generally, these results could indicate that 
members of the NSS family accommodate the structural and functional differences of 
substrates by subtle changes in the amino acids present in the substrate binding sites.  
Therefore, this could signify that changing the glutamic acid at the 494 position to an 
aspartic acid has no effect on the ability of the transporter to transport serotonin across 
the membrane.  
 
Interestingly, when mutated singly, no one of the five surveyed SERT inhibitor binding 
pocket residues is critical for high affinity binding of cocaine or the two SSRIs tested. 
The binding and uptake profiles of each of the mutants suggest differing roles with 
respect to substrates and inhibitors within the binding pocket of SERT.  The results 
gained from the screening are important points of reference and provide useful 
information for the refinement of the model.  The known SERT inhibitors used in the 
mutagenesis studies can be docked into mutant in silico SERT models, thus allowing 
investigators to understand if the orientation of the inhibitor is changing due to the 
mutation. The complete binding curves and substrate uptake curves present a 
comprehensive representation of the binding affinities and functionality of the mutants 
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being tested. The roles and suggested proximities of each amino acid to the SERT 
binding pocket(s) can impact the search for novel therapeutics.  This impact can be the 
altering of what structures and scaffolds could be used for the desired binding to SERT as 
well as how a novel therapeutics could interact with other proteins.  Unknown 
interactions of other proteins, such as 5-HT receptors, impact side-effects seen with 
potential antidepressant. 
 
If a mutant shows impaired SERT inhibitor binding, it would be consistent with the idea 
that the endogenous amino acid(s) plays a role in the binding process and would be 
partial confirmation that the binding pocket was identified. Prior mutants which were 
assessed for binding and uptake capacity were W103A, V489F, K490T, E493D, E494H, 
and E494T. Although the inhibitor binding screening only showed a significant 
difference between WT SERT and W103A, no changes occurred for the inhibitor binding 
affinities with W103A (Figure 5). SSRI serotonin uptake inhibition potency increased as 
much as 6-fold with the TM1 W103A mutation. The screening for inhibitor binding and 
substrate uptake at hSERT showed that the created mutants were functional and bound 
inhibitors and transported substrate. This functionality was at a higher rate than the non-
transfected naïve N2A cells (Figure 5). The results of the functionality of the transporter, 
as measured by the substrate uptake assay, correlated with the substrate uptake assay 
screening for most of the mutants. Further information on the residue in question can be 
gained by identifying which amino acids restore function at that position.   
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Net specific [
3
H]-serotonin uptake at W103A fell approximately 2-fold even though Bmax 
value for [
125
I]-RTI-55 saturation binding was not significantly affected (0.8 vs. 0.8nM).  
This suggests that, although binding is not altered with the alanine substitution, the ability 
of the transporter to transport substrate into the cell has been decreased. LeuT-TCA 
cocrystals show a salt bridge formed by the transmembrane where W103 is located and 
TM10 (Sinning et al., 2009). Specifically, this salt bridge is between Arg104 and Glu493, 
so the W103A mutant could be causing a rotation of TM1, thus disrupting the ability of 
the transporter to uptake substrate, making this result expected. 
 
Cocaine binding affinity decreased by 2-fold at the V489F mutant. This result suggests 
that V489 plays a role in cocaine binding, either by directly altering the binding of 
cocaine or by indirectly destabilizing the binding pocket. Surprisingly, affinity for the 
cocaine analog RTI-55 increased 2-fold at the V489F mutant as well as at the K490T 
mutant.  This result suggests that the TM10 V489 residue may be in the vicinity of the C-
3 tropane substituent of each drug.  Interestingly, the V489F substitution increased 
potency 2-fold to citalopram, but not to sertraline. Binding affinities to citalopram, 
sertraline, and cocaine were unaffected with the K490T mutation, as well as the uptake 
capacities. The differences seen between the binding and uptake profiles of the V489F 
mutant and the K490T mutant may suggest differing roles within the binding pocket of 
hSERT. 
 
An amino acid of SERT which is consistently suggested to have a role in binding via 
docking of known inhibitors is the negatively charged and hydrophilic E493. This 
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glutamic acid is thought to be a part of an extracellular charged gate between TM1 and 
TM10. Inhibitor binding can induce a formation of this salt bridge in SERT, thus 
substrate will be unable to translocate across the cell membrane.  Similar salt bridges are 
predicted in other MATs, thus making E493 a logical place to mutate and subsequently 
expect decreased inhibitor binding.  In our study, the conservative E493D mutation 
decreased binding affinity to citalopram, sertraline, and cocaine. It also decreased uptake 
inhibition of citalopram and sertraline by 3- and 7-fold, respectively. Although SSRI 
serotonin uptake inhibition potency increased as much as 6-fold with the TM1 W103A 
mutation, potency decreased 6-fold at the TM10 E493D mutant.  As discussed earlier, 
this could be due to the role played by the salt bridge between these transmembrane. 
 
At the next amino acid in the hSERT sequence, two mutants were created and tested for 
inhibitor binding and substrate uptake. E494H and E494T mutations decreased binding 
affinity to citalopram by 3- and 2-fold, respectively, and E494H decreased uptake 
inhibition of citalopram by 3-fold, but did not change uptake inhibition of at the E494T 
substitution. The lack of effect of the E494T substitution on the uptake inhibition of 
citalopram can be explained based on the charge-neutrality of threonine. Citalopram 
potency decreased 3-fold at E494H but not at the charge-neutral E494T substitution. The 
conservative change was not expected to create a large change in binding affinities or in 
the folding of the protein. 
 
Citalopram binding affinity decreased 3-fold at E493D and E494H SERT, and by over 2-
fold at E494T SERT. Interestingly, sertraline affinity decreased 7-fold with the 
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conservative E493 substitution but was unaffected by the E494 mutations.  Because the 
E493 and E494 side chains are expected to diverge in space, loss of one glutamate side 
chain should not be compensated for by the presence of the other. Net specific [
3
H]-
serotonin uptake at both E494 SERT mutants fell approximately 2-fold even though Bmax 
values for [
125
I]-RTI-55 saturation binding were not significantly affected.  This result 
implies the glutamic acid at 493 was unable to compensate for either of the mutations at 
494. As stated previously, this phenomenon of Net specific [
3
H]-serotonin uptake 
decreasing although Bmax values for [
125
I]-RTI-55 saturation binding were not 
significantly affected also occurred with the W103A mutant. 
 
The pharmacological data suggest that when mutated singly, no one of the five SERT 
vestibular pocket residues surveyed is critical for high affinity binding of cocaine or the 
two SSRIs tested. These results are consistent with similar vestibular pocket SERT 
mutants (Anderson, 2009).  If a mutant shows impaired SERT inhibitor binding, it would 
be consistent with the idea that the endogenous amino acid(s) plays a role in the binding 
process and would be partial confirmation that the binding pocket was identified.  
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Due to the many unwanted side-effects generated by current antidepressants, such as 
sleep disruption, weight gain, nausea, as well as slow onset of action (Moret et al., 2009), 
new therapeutics are sought for development. Drug development is an expensive and 
time-consuming endeavor. Recently, in silico models have not only been used to guide 
mutagenesis studies, but also to virtually screen compounds in order to identify potential 
new structural scaffolds. Virtual screening is an innovative approach to find choice 
molecules from a large collection of molecules which fit certain criteria, such as potential 
ability to bind to a specific protein or novel chemical structure. Our study aimed to 
identify compounds with new structural scaffolds that bind to SERT using computational 
models of SERT. 
 
The first hSERT model to be used for virtual screening was created by Martin Indarte.  
This model, referred to as the MI model, used two online alignment servers.  Molecular 
dynamics, which is a xxx used for complex systems in order to determine macroscopic 
thermodynamic properties of the system, were not performed on this model for the 
purpose of refinement. 
 
Compounds found to be hits using the MI SERT model were ranked based on the scoring 
function as described in the methods. Fourteen of the top hit compounds from the MI 
SERT model were acquired based on price and availability for pharmacological testing 
and labeled as the LM series.  One-point binding assays were performed using HEK cells 
expressing hSERT with the LM compounds.  [
125
I]-RTI-55 was used as the radioactive 
competitor in the binding experiments.  One-point binding assays using clomipramine 
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was performed as positive control and buffer as negative control and total [
125
I]-RTI-55 
binding.  
 
As seen collectively in Figure 6, none of the 14 compounds screened as “hits” from the 
MI SERT model inhibited [
125
I]-RTI-55 binding at SERT more than the arbitrarily-set 
threshold of 50%.  This threshold was set as a standard guidepost based on the high 
concentration of drug (10μM) used to compete with [125I]-RTI-55 binding.  When 
homology models are used without refinement, and without X-ray structures of the 
targets, only low micromolar (1-10uM) activities can be visualized (Zuccotto et al., 2001). 
Also, the number of compounds that are found as hits is typically very low (Schneider 
and Bohm, 2002), so these results can be viewed as a reason to revise and refine the 
SERT model. 
 
The second hSERT model to be used for virtual screening was created by Sankar 
Manepalli.  This model, referred to as the SM model, used alternative methods to the MI 
model.  Four different alignments (Yamashita, Beuming, JACS, etc) were used to create 
preliminary SERT models.  Using additional alignment can improve the precision of the 
model, as the eventual model was chosen based on a final alignment which was created.  
The SM model was also refined in two different ways.  Ramachandran plots, which are 
used as a way to visualize backbone dihedral angles of amino acid residues in protein 
structures, was used in with the in silico SERT model and highlighted outliers from the 
model.  The highlighted outliers were minimized to determine their reason for being 
outliers.  Loops, which are a part of the protein that interact with the surrounding aqueous 
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environment, tend to have charged and polar amino acids and are frequently a component 
of active sites.  Refinement of these loops was also done via visual inspection of the 
model.  Other important differences that could lead to differences in screening outcomes 
include the orientation of the E493 and E494 functional groups.  The MI model shows 
these functional groups to be both facing toward the inhibitor binding pocket, while the 
SM pocket determined the E494 functional group to be facing away from the pocket.  
The SM model orientation of these two amino acids is seen as a confirmation as to why 
the neighboring glutamic acids do not compensate for the other upon mutation of one. 
 
Using the SM model, two sets of compounds were chosen for pharmacological testing.  
The first set acquired and tested were 10 compounds which were of higher ranking and 
labeled as the SM series. The second set were 11 compounds which were of lower 
ranking and labeled as the MS series.  One-point binding assays were performed using 
HEK cells expressing hSERT, hDAT, or hNET with the hit compounds from the SM 
series from the MI SERT model.  The compounds were tested in not only cells expressing 
hSERT, but also cells expressing hDAT and cells expressing hNET due to the similarity 
among the monoamine transporters.   
 
At the cells expressing hNET, the SM series compounds did not significantly inhibit 
[
125
I]-RTI-55 binding in a one-point binding assay.  Although there is a large amount of 
sequence similarity between the monoamine transporters, differences may exist between 
the inhibitor binding pockets which may make some compounds more selective for a 
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specific transporter over the others.  In this case, the compounds screened as hits using a 
hSERT model did not inhibit hNET. 
 
At the cells expressing hDAT, one compound from the SM series inhibited [
125
I]-RTI-55 
binding in a one-point binding assay.  Although SM14 displayed no significant binding to 
hSERT, it appeared to inhibit [
125
I]-RTI-55 binding to hDAT by 40%. A binding assay 
was completed and found that this compound had a low uM affinity to hDAT and 
inhibited substrate translocation at similar concentrations.  The amount of sequence 
similarity between the dopamine transporter and the serotonin transporter makes it more 
likely for a compound screened to dock at the SERT pocket to also dock at the DAT 
pocket. 
 
At the cells expressing hSERT, two compounds from the SM series inhibited [
125
I]-RTI-
55 binding in a one-point binding assay.  Labeled as SM10 and SM11, these compounds 
were not only found to bind to hSERT with appreciable affinity, but were also found to 
have a selective affinity for SERT over the dopamine transporter and norepinephrine 
transporter.  These results are encouraging, as the compounds emerged from a virtual 
screening experiment utilizing a large database and a comparative SERT protein model 
with low sequence similarity to its template. 
 
The second set were 11 compounds which were of lower ranking than the SM series, and 
were labeled as the MS series.  One-point binding assays were performed using HEK 
cells expressing hSERT, hDAT, or hNET with the hit compounds from the MS series 
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from the MI SERT model.  Just like the previous compounds found via virtual screening 
of these SERT models, the compounds were tested in not only cells expressing hSERT, 
but also cells expressing hDAT and cells expressing hNET due to the similarity among 
the monoamine transporters.  Unfortunately, none of this second set of lower ranking hit 
compounds were found to inhibited [
125
I]-RTI-55 binding at SERT more than the 
arbitrarily-set threshold of 50%. 
 
The differences in the number of compounds that emerge as hit compounds can be a 
consequence of the differences in sequence alignments and models.  Models are not 
perfect, but can be useful.  This model evolved due to new information from 
pharmacological testing and mutagenesis, which lead to the discovery of two novel 
scaffolds which are capable of inhibiting a cocaine analog from binding to the 
transporter.   
 
Future directions for this research will aim to further define the SERT inhibitor binding 
pockets.  One promising avenue of research would be to localize SSRI-based 
photoprobes to the SERT S1 or S2 binding pocket.  This would be done using the analogs 
created with clickable handles and pharmacologically tested at SERT. A SERT-ligand 
irreversible covalent could be induced by exposing the protein-ligand complex to 
ultraviolet light (Lapinsky, 2012).  Subsequently, liquid chromatography-mass 
spectrometry (LC/MS) would be used for its high sensitivity and selectivity to identify 
specific acids which form bonds with the probe.  Another promising avenue of research 
would be the behavioral testing of the VS compounds found to bind with high affinity to 
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the SERT in an in vivo model of depression or anxiety.  Positive results would highlight 
the importance and advantages of using an in silico model for the discovery of novel 
therapeutics. 
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